The Latest Breaking News from uniQure

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

uniQure shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

The FDA just approved its most expensive drug ever — a hemophilia gene therapy from CSL and UniQure — and QURE stock popped Wednesday.

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.  Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings:

  uniQure (NASDAQ:QURE) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

  uniQure (NASDAQ:QURE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings uniQure reported an EPS of $0.17.